Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 14;4(1):vdac166. doi: 10.1093/noajnl/vdac166

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Tissue-wide integrated intensity analysis reveals an overexpression of OATP1A2, 2B1, 1C1 and 4A1 in GBM tissue. Representative immunohistochemical labelling of OATP1A2/OATP2B1/OATP1C1/OATP4A1, as labelled with Hoechst nuclear counterstain in non-tumour (A) and GBM (B) tissue; scale bar = 100 μm, inset = 75 μm. The mean integrated intensity of OATP1A2, 2B1, 1C1, and 4A1 was compared between GBM and non-tumour with a non-parametric Mann-Whitney test (C–F), data compared between tumour (n = 25 cases) and non-tumour (n = 8 cases) tissue with Mann-Whitney test, presented as violin plot, median ± upper and lower quartiles. qRT-PCR quantifying the mRNA expression of OATP1A2, 2B1, 1C1 and 4A1 in GBM tumour tissue compared to non-tumour MTG brain tissue (G–J), data represents the mean ± SD of GBM (n = 3 cases) and non-tumour (n = 3 cases) fresh-frozen cases. **P < 0.01, ***P < 0.001, ****P < 0.0001.